EYPT Stock Overview
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom.
EyePoint Pharmaceuticals Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$7.75|
|52 Week High||US$21.50|
|52 Week Low||US$7.00|
|1 Month Change||-14.46%|
|3 Month Change||-36.21%|
|1 Year Change||-12.13%|
|3 Year Change||-52.45%|
|5 Year Change||-55.97%|
|Change since IPO||-75.48%|
Recent News & Updates
|EYPT||US Pharmaceuticals||US Market|
Return vs Industry: EYPT underperformed the US Pharmaceuticals industry which returned 10.4% over the past year.
Return vs Market: EYPT exceeded the US Market which returned -21.2% over the past year.
|EYPT Average Weekly Movement||9.3%|
|Pharmaceuticals Industry Average Movement||11.9%|
|Market Average Movement||8.1%|
|10% most volatile stocks in US Market||16.8%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: EYPT is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: EYPT's weekly volatility (9%) has been stable over the past year.
About the Company
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.
EyePoint Pharmaceuticals Fundamentals Summary
|EYPT fundamental statistics|
Is EYPT overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|EYPT income statement (TTM)|
|Cost of Revenue||US$41.53m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.97|
|Net Profit Margin||-172.48%|
How did EYPT perform over the long term?See historical performance and comparison
Is EYPT undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 1/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for EYPT?
Other financial metrics that can be useful for relative valuation.
|What is EYPT's n/a Ratio?|
Price to Sales Ratio vs Peers
How does EYPT's PS Ratio compare to its peers?
|EYPT PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
WVE Wave Life Sciences
AERI Aerie Pharmaceuticals
EYPT EyePoint Pharmaceuticals
Price-To-Sales vs Peers: EYPT is good value based on its Price-To-Sales Ratio (6.8x) compared to the peer average (8.2x).
Price to Earnings Ratio vs Industry
How does EYPT's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?
Price-To-Sales vs Industry: EYPT is expensive based on its Price-To-Sales Ratio (6.8x) compared to the US Pharmaceuticals industry average (4.1x)
Price to Sales Ratio vs Fair Ratio
What is EYPT's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||6.8x|
|Fair PS Ratio||3.3x|
Price-To-Sales vs Fair Ratio: EYPT is expensive based on its Price-To-Sales Ratio (6.8x) compared to the estimated Fair Price-To-Sales Ratio (3.3x).
Share Price vs Fair Value
What is the Fair Price of EYPT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate EYPT's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate EYPT's fair value for valuation analysis.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate EYPT's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is EyePoint Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: EYPT is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: EYPT is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: EYPT is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: EYPT's revenue (31.3% per year) is forecast to grow faster than the US market (8.2% per year).
High Growth Revenue: EYPT's revenue (31.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if EYPT's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has EyePoint Pharmaceuticals performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: EYPT is currently unprofitable.
Growing Profit Margin: EYPT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: EYPT is unprofitable, and losses have increased over the past 5 years at a rate of 10% per year.
Accelerating Growth: Unable to compare EYPT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EYPT is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16.9%).
Return on Equity
High ROE: EYPT has a negative Return on Equity (-40.23%), as it is currently unprofitable.
Discover strong past performing companies
How is EyePoint Pharmaceuticals's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: EYPT's short term assets ($219.6M) exceed its short term liabilities ($32.0M).
Long Term Liabilities: EYPT's short term assets ($219.6M) exceed its long term liabilities ($45.8M).
Debt to Equity History and Analysis
Debt Level: EYPT has more cash than its total debt.
Reducing Debt: Insufficient data to determine if EYPT's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: EYPT has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: EYPT has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of 13.6% each year.
Discover healthy companies
What is EyePoint Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate EYPT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate EYPT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if EYPT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if EYPT's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as EYPT has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Nancy Lurker (65 yo)
Ms. Nancy S. Lurker serves as a Member of Advisory Group at Novo Holdings A/S. She has been the Chief Executive Officer and President of EyePoint Pharmaceuticals, Inc. (formerly known as pSivida Corp.) sin...
CEO Compensation Analysis
Compensation vs Market: Nancy's total compensation ($USD3.62M) is above average for companies of similar size in the US market ($USD1.83M).
Compensation vs Earnings: Nancy's compensation has increased whilst the company is unprofitable.
Experienced Management: EYPT's management team is considered experienced (3.1 years average tenure).
Experienced Board: EYPT's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 18.5%.
EyePoint Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources
- Name: EyePoint Pharmaceuticals, Inc.
- Ticker: EYPT
- Exchange: NasdaqGM
- Founded: 1987
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$263.865m
- Shares outstanding: 34.05m
- Website: https://eyepointpharma.com
Number of Employees
- EyePoint Pharmaceuticals, Inc.
- 480 Pleasant Street
- Suite B300
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/07/03 00:00|
|End of Day Share Price||2022/07/01 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.